Spyre reports Q3 2026 results, SPY003 data complete IBD monotherapy trio
Spyre also dropped SPY072 from rheumatic disease development, started a new HS trial, and reported pro forma cash of $1.5 billion with runway into the second half of 2029.
SEC filing